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ABSTRACT  
Within the wide range of nitrogen-containing heterocyclic compounds, the derivatives of 1,8-naphthyridine (NPTR) have gained a rising interest 
due to their reported versatile biological activities. The derivatives of NPTR scaffold are found to invite special interest from researchers nowadays 
on the significance of their manifestations of multiple attractive pharmacological activities which establish them as an effective and versatile tool in 
pharmaceutical chemistry and drug discovery. The diverse biological activities mainly include anti-inflammatory, antimicrobial, antiviral, 
anticancer, antihypertensive and analgesic activities. Novel NPTR scaffold has emerged its potency to treat neurological diseases like depression 
and Alzheimer's disease. Further these agents possess different inhibitory activities, such as anti-HIV, anti-osteoporotic, αvβ3 antagonism, 
antimalarial, platelet aggregation, anti-oxidant, anti-allergic, gastric antisecretory, anticonvulsant, epidermal growth factor receptor (EGFR) 
inhibition, protein kinase inhibition, ionotropic properties, β3
Keywords: 1,8-Naphthyridine (NPTR), Quinolone, Antimicrobial activity, Anticancer activity, Antitumor, Anti-inflammatory activity, Antimalarial 
antihypertensive, Antiplatelet activity, αvβ3 antagonist 
 antagonism, phosphodiesterase 4 (PDE 4) inhibitions, adenosine receptor agonistic 
activity, adrenoceptors antagonism and DNA stabilizing activity, etc. In this review, we highlight the updates of different 1,8-naphthyridine 
derivatives and explain the key data available in the context of various biological activities of NPTR derivatives available from the literature. This 
may direct opportunity in researches in the synthesis of novel medicinal agents and the development of new heterocycles for modification of 
existing biological actions as well as evaluation of other possible pharmacological activities. 




Nowadays, researchers are concentrating interests towards the 
introduction of novel and safe therapeutic agents for getting medical 
significance [1]. The nitrogen-containing heterocycles are the major 
class of chemical compounds in therapeutic uses. Naphthyridine is 
one of such heterocycle. The name naphthyridine is often known to 
the fused-ring system, which is formed by the fusion of two pyridine 
rings with two neighboring carbon atoms, and every ring system 
having only a single nitrogen atom. This name was first 
recommended by A. Reissert, who prepared the first series of 
naphthyridine in 1893. However 1, 8-naphthyridine is known as the 
naphthalene analog of pyridine [2]; these ring systems have given 
different names, like “benzodiazepines”, “pyridinopyridins” etc. 
depending on the arrangement of the nitrogen atom(s). Six different 
naphthyridine systems (fig. 1), namely 1, 5-Naphthyridine (1) 1, 6-
Naphthyridine (2) 1, 7-Naphthyridine (3) 1, 8-Naphthyridine (4) 
2,6-Naphthyridine (5) and 2, 7-Naphthyridine (6) are existing at the 
present time and amongst them 1, 8-Naphthyridine is the novel class 
of heterocycle [3-8].  
 
 
Fig. 1: Naphthyridines 
The naphthyridine ring systems are generally prepared from 
aminopyridines by using various types of cyclization reactions, very 
similar to those processes employed in quinoline chemistry. In a few 
cases, they are prepared by the degeneration of a polynuclear 
compound or by ring resizing of properly established phthalimides 
(Sliraup, Doebner-Miller, Doebner, Knorr) [9]. Consequently, a huge 
quantity of 1, 8-naphthyridine have been synthesized and few of 
them have reached the clinical stages. These derivatives carry 
versatile biological activities such as anticancer, cytotoxic, anti-
inflammatory, antimicrobial, analgesic, antidepressant, antiepileptic, 
antihypertensive, etc. Many 1, 8-naphthyridine analogs are found to 
exhibits significant biological activities and have been established as 
valuable agents in drug research.  
1, 8-Naphthyridine (NPTR) 
Amongst the six isomeric pyridopyridines, the derivative having 1, 8-
naphthyridine (NPTR) ring gained the importance in the last 25 y. This 
group of derivatives has drawn interests mainly owing to the NPTR 
ring system which is abundant in lots of active derivatives including 
inherent substances and possesses different biological behavior. The 
quantity of publications and patents related to the chemical and 
biological activities of 1, 8-naphthyridines derivatives which were 
issued and published during this era is more than the number of 
research on other pyridopyridines in the previous more than 90 y. In 
the few years, more than 900 publications have been published on the 
relevant topic, amongst which about 200 were patents [10]. A large 
number of these topics are focused on specific prospects of biological 
activities and assays. Clinically, the derivatives are more acceptable 
because of its potent efficacy and minimal side effect. So, by looking at 
its clinical output and safety margin, 1, 8-naphthyridine nucleus is 
becoming the prime choice for the researchers for further 
investigations [11, 12]. Patent of some 1, 8-naphthyridine derivatives 
are summarized in the table. Currently, 1, 8-naphthyridine represents 
an extensively used scaffold with a number of attractive uses in the 
different pharmacological areas. Thus, a variety of pharmacological 
activities have been described and reported until now [13, 14]. Some 
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of the modern drugs of naphthyridine moieties (fig. 2) include nalidixic 
acid (7), tosufloxacin (8), trovafloxacin mesylate (9), enoxacin (10), 
alatrofloxacin mesylate (11), gemifloxacin (12), and voreloxin (13) 
which already exist in the market. 
  





Publication date Title of publication Inventors 
1 US 6,331,548  Dec. 18,2001 1-Cycloalkyl-1,8-naphthyridin-4-one Derivative as type iv 
Phosphodiesterase inhibitor 
Shimamoto et al. 
[132]. 
2 US 6,340,690  Jan. 22, 2002 Antiviral methods using [1,8] naphthyridine derivatives Bachand et al. [133]. 




4 WO 03/027112 Apr. 3,2003 1, 8-Naphthyridine derivatives as antidiabetics Yamin et al. [135]. 
5 US 6,605,614  Aug. 12, 2003 [1,8] naphthyridine derivatives having antiviral activity Bachand et al. [136]. 
6 US, 
20040014751A1 
Sep. 26, 2001 1,8-Naphthyridine derivatives and their use to treat diabetes and 
related disorders  
Yamin et al. [137]. 
7 US 7,067,528 B2 Jun. 27, 2006 1, 2-Dihydro-2-oxo-1, s-naphthyridine derivative Muraoka et al. [138]. 
8 US 7,109,196 B2 Sep. 19, 2006 1,8-Naphthyridine derivatives and their use to treat diabetes and 
related disorders 
Yamin et al. [139]. 
9 US 7,163,948 B2 Jan. 16, 2007 Heterocyclic substituted 1,4-dihydri-4ox9-1,s-naphthyridine analogs Whitten et a1. [140]. 
10 US, 
20100056563A1 
Mar. 4, 2010 Novel 1,8-naphthyridine compounds Deodialsingh et al. 
[141]. 
11 EP1695974B1 Mar, 17, 2010 1,8-Naphthyridines as CRF antagonists Fabio et al. [142]. 
12 US 7,790,716 B2 Sep. 7, 2010 Fab I inhibitors Miller et al. [143]. 
13 WO2005091857A3 Oct 5, 2006 1,6-Naphthyridine and 1,8-naphthyridine derivatives and their use to 
treat diabetes and related disorders  
Rainer Heurich 
[144]. 
14 US, 8124773B2 Feb. 28, 2012 1,8-Naphthyridine compounds for the treatment of cancer Adelman at al. [145]. 
15 US 
2012/0316166A1 
Dec. 13, 2012 Hetarylaminonaphthyridines Jonczyk et al.[146]. 
16 US 8,470,847 B2 July. 25, 2013 Derivatives of 7-alkynyl-1,8-naphthyridones,  
preparation method thereof and 2011‘use of same in therapeutics 
Alam et al. [147]. 
17 US 8,765,954B2 Jul. 1, 2014 1,8-Naphthyridine compounds for the treatment of cancer Adelman et al. [148]. 
18 US, 8,912,216 Dec. 16, 2014 Hetaryl-[1,8]naphthyridine derivatives Jonczyk et al. [149]. 
19 US, 8,952,164B2 Feb. 10, 2015 R-7-(3-aminomethy-4-methoxyimino-3-methyl-pyrrolidin-1-yl)-1-
cyclopropyl-6--fluoro-4-oxo-1,4-dihydo-[1,8]naphthyridine-3-
carboxylic acid and l-aspartic acid salt, process for the preparation 
thereof and pharmaceutical composition comprising the same for 
antimicrobial 
Choi, et al. [150] 
20 US 20150250775 Sep. 10, 2015 Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-
(methylamino)-1-pyrrolidinyl]-4-ox-o-1-(2-thiazolyl)-1,8-






Fig. 2: Marketed antibiotics having a 1,8-naphthyridine nucleus 
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Nalidixic acid (7) is useful in the management of various urinary 
tract infections (UTIs) where the gram-negative bacteria are 
responsible for the disease [15, 16]. Tosufloxacin, a fluoroquinolone 
(8) has potent broad-spectrum activity and its greater activity is 
found against clinically important gram-positive organisms 
comparable to that of other fluoroquinolones such as ciprofloxacin 
and ofloxacin [17]. Trovafloxacin (9) is an important drug active 
against Gram-negative species. It exhibits 8 to 16 time greater 
activity than that of either ofloxacin or ciprofloxacin [18]. Enoxacin, 
a quinolone (10) has a broad-spectrum antibacterial activity and is 
used mainly in the treatment of UTIs and STDs [19]. Alatrofloxacin, a 
fluoroquinolones antibacterial compound (11) has outstanding 
activity against bacteria [20]. Gemifloxacin mesylate (12), a synthetic 
well known broad-spectrum antibacterial agent is generally used 
orally [21]. Voreloxin (13) a novel NPTR derivative, which is 
structurally associated with the quinolone antibiotics, a chemical 
group not known previously for anticancer properties [22-27].  
Synthetic analogs of 1, 8-naphthyridine, exhibiting various 
pharmacological activities 
Antimicrobial activity  
Antibiotics are the most imperative agents in healing bacterial 
infections and have an important benefit for the health-related 
quality of our lives since their introduction in the medical field. On 
the other hand, over the past few decades, these health profits are 
below threat as several regularly used antibiotics become less 
effective against some bacteria and certain illnesses. The thoroughly 
increasing, the occurrence of multi-drug resistant against antibiotics, 
microbial infections in the last few decades have developed into a 
severe health care problem. To investigate novel antibacterial drug 
will thus persist as an essential and demanding task for the 
researcher. Development and advancement in new antimicrobial 
drugs are yet in the demand of the day due to microbial resistance, 
whereby 1, 8-Naphthyridines are imperative components in novel 
antibacterial drug discovery [28-30]. Gohil et al. [31] synthesize new 
chromeno [4,3-f] [1,8] naphthyridines analogs (14a-d) by a multi-
component reaction and evaluate for their antimicrobial activity. 
The compounds with 4-fluorophenyl (14a),3-trifluoromethyl (14b), 
6-Amino-8-(4-fluorophenyl) (14c) and 6-Amino-12-methoxy-8-(3-
(trifluoro-methyl)phenyl)-(14d) shows excellent antimicrobial 
activity against both type of bacterial strains with MIC value 50 
mg/ml, and also the compounds (14a) and (14c) exhibit excellent 
antifungal activity with MIC value 250 mg/ml. The activities might 
be attributed due to the substitution of electron withdrawing group 
(F, CF3). Furthermore, derivatives having methyl group exhibit a 
reasonable activity, In addition, triazole substituted derivatives 
exhibit the excellent antifungal activity with MIC value 250 μg/ml). 
 
 
Structure-activity studies indicate that 1, 4-dihydro-4-oxo-3-pyridine-
carboxylic acid moiety is necessary for antimicrobial activity. The 
pyridone scaffold has to be annotated by an aryl ring. Isosteric 
replacements of nitrogen atom for carbon atoms at positions 8 are 
reliable with the protection of antimicrobial activity. The addition of 
substitutes at position 2 significantly decline activity; positions 5, 6, 7 
and 8 of the annulled rings could be substituted with excellent activity. 
For example, piperazinyl and 3-aminopyrrolidinyl substitutions at 
position 7 show better activity with compounds of the quinolone class 
against the gram-negative strain of P. aeruginosa. Substitution of 
fluorine atom also significantly enhances antibacterial activity [32]. 
Substitution of alkyl at the 1-position is necessary for antibacterial 
activity, small alkyl derivatives normally having better efficacy. 
Addition of aryl at the 1-position is also steady with antimicrobial 
activity, with a 2, 4-difluorophenyl group provides the best efficacy. 
Ring condensations at the 1, 8 positions also produce active 
compounds. Arayne et al. [33] synthesize different enoxacin analogs 
via nucleophilic substitution at the C3 position of the drug by primary 
aromatic amines. The free carboxylic acid group is used as a target for 
the synthesis of amide derivatives, and the result of functional group 
substitution on various biological activities of the parent compounds 
was studied. The derivative (15-19) exhibits antimicrobial activity 
against both the strains of bacteria through better activity, is found in 
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Lv et al. [34] synthesize new naphthyridone analogous having 
mono/difluoro-methyloxime pyrrolidine ring system with 
remarkable improvement in lipophilicity (20 and 21). In in vivo 
experiments, a compound with 7-(3-aminomethyl group) (21) 
shows more activity than that of its parent drug against the test 
bacterial strains, and particularly its activity is 5.2-6.1 times more 
active than ciprofloxacin and gemifloxacin against gram-negative 
bacteria P. aeruginosa with ED50
 
 value 21.27 mg/kg. 
 
Feng et al. [35] synthesize new gemifloxacin analogs having 
substituted benzyloxime group with significant enhancement in the 
lipophilic property. Most of the compounds show significant potency 
against tested strains including methicillin-resistant S. epidermidis 
and S. aureus (MIC: <0.008-8 µg/ml). Compound (22) a 2, 5-
Dimethoxyl derivative show 2-128 and8-2048 times more activity 




Aggarwal et al. [36] synthesize new nalidixic acid based 1, 3, 4-thia/oxa 
diazoles, their bis mercapto, sulfones, thioethers, and Mannich bases 
derivatives (23-25). These compounds show a moderate to excellent 
antibacterial activity against the tested bacterial strain. The compounds 
having thiadiazole moiety show better antimicrobial activity as 
compared to compounds having oxadiazoles moiety. Compound (23) a 
thiadiazole derivative show good activity against K. pneumoniae, B. 
subtilis, and P. aeruginosa with a MIC value from 6.25–125 µg ⁄ ml. 
 
 
Fadla et al. [37] synthesize a new series of Schiff bases and evaluate 
their antimycobacterial activity. The lead Schiff base N'-(1-benzyl-2-
oxoindolin-3-ylidene) substituted 1, 8-naphthyridine-3-carboxylic 
acid (26) exhibits remarkable inhibitory activity against four 
Mycobacterium strains: M. cheleneo, M. intercellulari, M. xenopi, and 
M. smegmatis. The para substitution, of a benzyl moiety with 
electron withdrawing groups, in N-benzylisatins is seven-times 
more active as shown by N'-(1-(4-chlorobenzyl)-2-oxoindolin-3-
ylidene) substituted 1, 8-naphthyridine-3-carboxylic acid (27) (Z)-1-
ethyl-N'-(1-(4-fluorobenzyl)-2-oxoindolin-3-ylidene) substituted 1, 
8-naphthyridine-3-carboxylic acid (28a) and (Z)-1-ethyl-7-methyl-
N'-(1-(4-nitrobenzyl)-2-oxoindolin-3-ylidene) substituted 1, 8-
naphthyridine-3-carboxylic acid (28b) with fluoro, p-chloro and 
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Jalal et al. [38] synthesize various modified 4-morpholino-
methyl-1.8-naphthyridine derivatives and evaluate their 
antitubercular activities against M. tuberculosis strain H37Rv in 
vitro.  
The compound 1,8-naphthyridine analog (29) with a 6-amino-2-
(4'-methoxybenzylamine-4-morpholinomethyl-7-morpholino-
substituent shows good activity with a MIC of 0.25 μg/ml and 
offers a promising new lead for further development. 
  
 
The field of coordination chemistry of metal complexes is 
growing rapidly because of its versatile and broad utilization in 
medical and biomedical fields [39]. The biological effectiveness 
of metal ions draws great interest to many researchers for the 
development and application of inorganic compounds with 
possible biologically active ligands. Quinolones are having 4-oxo-
3-carboxylic-1, 4-dihydroquinoline frame is a bioligand, having 
bactericidal properties, good oral absorption, outstanding 
bioavailability, and high penetration power into tissues. 
Nalidixic acid (Nal) is the first member of quinolones [40]. It 
effectively inhibits the growth of gram-negative bacteria and is 
used for the treatment of different infectious diseases like UTIs, 
typhoid fever, bone-joint infections, respiratory infections, soft 
tissue infections, community-acquired pneumonia, and sexually 
transmitted diseases.  
Zakya et al. [41] synthesize various complexes of nalidixic acid with 
addition of Zn (II), Fe (III), Ca (II), Mg (II), and VO (II) ions and evaluate 
their antibacterial potentialities. The antibacterial activities of the 
synthesized compounds were tested against gram-negative and gram-
positive bacteria, i.e. E. coli, S. albus as well as fungi, such as A. flavus 
and A. niger. The ligand coordinates in a bidentate manner via one 
carboxylate oxygen atom and the oxygen atom of the pyridine 
carbonyl group. The Zn (II) complex (30) exhibits the best activity 
amongst all. The biological activities, find out in the following order: Zn 
(II)-Ndx>VO (II)-Ndx>Fe (III)-Ndx>Mg (II)-Ndx>Ca (II)-Ndx. 
  
 
Fig. 3: Crystal structure of [Ag(Nal)2] Complex [Sourse: Debnath et al. Rus J Gen Chem 2013;83:2488–2501] 
 
Debnath et al. [42] synthesize a new binuclear square planar 
complex of nalidixic acid with silver (Ag) metal ion (fig. 3) 
having the molecular formula as [Ag(Nal) 2
 
]. The ligand is 
bonded to Ag (I) ion via the carboxylate oxygen and pyridone. 
The synthesized metal ion complex exhibits excellent antifungal 
activity as compared to that of nalidixic acid when tested against 
four fungal strains, S. rolfsii, R. solani P. aphanidermatum, and R. 
bataticola. Saleh et al. [43] report an easy and regioselective 
synthesis of 2- chloro-3- formyl-1, 8-naphthyridine, through 
Vilsmeier-Haack cyclization of N-(pyridine-2-yl) acetamide. The 
1,2,4-triazole, 1,3,4-thiadiazol and 1,3,4-oxadiazole derivative, 5-
(2-chloro-1, 8-naphthyridine-3-yl)-4H-1,2,4-triazole-3-thiol (31), 
5-(2-chloro-1, 8-naphthyridine-3-yl)-1,3,4-thiadiazol-2-amine (32) 
and 5-(2-chloro-1, 8-naphthyridine-3-yl)-1,3,4-oxadiazole-2(3H) 
-thione 33) demonstrate good antibacterial activities against S. 
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Gao et al. [44] synthesize new tricyclic fluoroquinolones, (34a-h) 
containing an efficient Mannich-base moiety at the C-8 position. The 
compounds (34e-g) with a piperazine side chain show similar 
antibacterial activity than that of ciprofloxacin. In addition, the 
compounds also show broad-spectrum antibacterial activity, 




Acosta et al. [45] synthesize various 1, 8-naphthyridine derivatives 
by microwave-assisted synthesis with heterocyclic o-aminonitriles 
and cyclic ketenes catalyzed by ZnCl2
 
 and produce a series of 
pyrazolo [3,4-b] [1, 8] naphthyridine-5-amines. The derivatives 
with a 4-p-tolyl substituent at naphthyridine skeleton (35a, 35b 
and 35c) are most active against C. albicans, which appear to be 
linked with their corresponding hydrophobicity. Amongst these 
compounds, 3-methyl-1-phenyl-4-p-tolyl substituted, 1, 8-
naphthyridine-5-amine (35a), having a cyclohexyl fused ring, 
exhibits excellent activity. 
 
Donalisio et al. [46] study the effects of 1, 8-naphthyridine derivatives 
(36) that effectively inhibit the transcription, regulated by the long 
control region of human papillomavirus
 
 (HPV) genome. They 
investigate with a sequence of analogs to get more effective 
derivatives like quinoline and thiazol substituted piperazine at 7 
positions (37) and (38). These compounds have the ability to down-
regulate E6 and E7 transcripts in human papillomavirus (HPV-16) 
positive cervical cancer CaSki cells. The 1,8-naphthyridines appear as a 
satisfactory beginning mark for the development of novel compounds 
effective for the management of HPV-induced cervical cancer. 
  
Sakram et al. [47] Synthesise substituted 1,8-naphthyridines based 
on 2-aminonicotinaldehyde and evaluate their antimicrobial 
property against various bacterial strains like S. aureus, B. subtilis, E. 
coli, and K. pneumonia and anti-fungal activity toward A. flavus and F. 
oxysporum. Compounds 2-Butyl-3-iodo-1,8-naphthyridine (39a), 2-
Hexyl-3-iodo-1,8-naphthyridine (39b) and 3-Iodo-2-phenyl-1,8-
naphthyridine (39c) show maximal zone of inhibition against the 
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Valadbeigi and Ghodsi [48] synthesize a series of N-[2-(8-methoxy-2H-
chromen-2-one)ethyl] piperazinyl quinolones having a carbonyl linked 
functional groups on the ethyl spacer of coumarin and piperazine rings 
and observe their antimicrobial activities against both gram-positive and 
gram-negative strain, B. subtilis PTCC 1207, E. coli PTCC 1047 and a 
fungus strain, C. kefyr ATCC 38296 respectively. Amongst these, the 
compound with 7 substituted piperazine and chromen moiety (40) 
shows the most potent in vitro antimicrobial activity. 
 
 
Gençer et al. [49] synthesize a new series of 7-substituted 
fluoroquinolones and evaluate their antimicrobial activity against 
both gram-positive and gram-negative bacteria strain. Compound 
bearing a 4-dimethylaminopropylpiperazin-1-yl substituent (41) 
show good antibacterial activity and DNA gyrase inhibition similar 
to that of ciprofloxacin, moxifloxacin, and trovafloxacin with the 
MIC90 value 1.95 μg/ml against S. aureus, and E. coli. 
Antihistaminic activity  
Sherlock et al. [50] describe a new class of antiallergic compounds, 
the substituted l, 8-naphthyridine-2 (lH)-ones which associate in the 
prohibition of the discharge of the leukotrienes and sulfidopeptide. 
Structure-activity relationship studies of the lead scaffold in this 
series, l-phenyl-3-n-butyl 4-hydroxynaphthyridine-2 (lH)-one 
identify three derivatives of importance, 1, 8-naphthyridine 
substituted with l-phenyl (42a) 1, 8-naphthyridine substituted with 
 chlorophenyl) (42b) and 1, 8-naphthyridine substituted with-׳3)-1
 methoxyphenyl) (42c). Compound (42a) is chosen as the lead-׳3)-1
for preclinical development as an antiallergic compound. 
Nishikawa et al. [51] synthesize oxo-pyridine carboxamide 
derivatives and evaluate their antiallergic activities. The 1, 8-
naphthyridine-3-carboxamides (43a and 43b) is found potent 
antiallergic agent in the rat passive cutaneous anaphylaxis (PCA) 
test and also exhibit excellent inhibitory activity in vitro than that of 




As Antihypertensive agents 
Different cardiovascular diseases like ischemia, hypertension, and 
arrhythmias are treated by β-adrenoreceptor antagonists. Though β-
adrenergic inhibitors are incredibly uniform in their chemical structures, 
only a few β-blockers related to 1, 8-naphthyridine derivatives have 
been described till date [52]. Badawneh et al. [53] synthesize various 
substituted 1, 8-naphthyridine analogs, and study their antihypertensive 
activity. The 4-(N-methylencyclo-alkylamino)-1, 8-naphthyridine 
derivatives with various substitutions in positions 2 and 7 show 
satisfactory levels of potency (pIC50>5where as the compound (44) N-
ethoxycarbonylpiperazin-1-yl derivative) reached a really interesting 
value (pICR50 Rvalue of 6.92). The β-antagonist activity of (R, S)-(E)-oxime 
ethers of 2, 3-dihydro-1, 8-naphthyridine and of 2, 3-dihydrothiopyrano 
[2, 3-b] pyridine (45) has βR3R-blocking properties, It is notable that these 
compounds, have bulky substituents at position 7 and with these 4-t-
butylphenoxy or 4-chloro-phenoxy groups show an impressive 
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Jalal et al. [54] synthesize new derivatives of 1, 8-naphthyridine 
from 7-amino-2-hydroxy-4-morpholinomethyl-1,8-
naphthyridine. The analogs of either 7-hydroxy-2-N-
ethoxycarbonylpiperazine or a 7-hydroxy-2-piperazine 
substituent (46a and 46b) show a higher affinity towards β 1 
 
Anticancer and antitumor activity 
receptors. 
Cancer or malignancy is a most important burden of disease of 
worldwide, it is a group of diseases characterized by uncontrolled 
growth of cells and has potential to occupy or spread to other 
parts of the body [55-57]. A number of anticancer agents are at 
present in clinical use. To find new anticancer agents, the 
discovery of a number of 1, 8-naphthyridine (NPTR) derivatives is 
the new addition. Recently, NPTR and quinolines well-known 
heterocyclic compounds are being introduced in cancer 
chemotherapy and in this circumstances, ‘Voreloxin’ is already in 
clinical use [58]. The entire NPTR derivatives exhibit limited 
cytotoxic activity against murine P388 leukemia cells. Eweas et al. 
[59] synthesize new 2, 7-Dimethyl-1, 8-naphthyridine derivatives 
substituted with Schiff’s bases, Mannich bases N-β-glycosides, 
pyrazolone, and S-alkylated. Furan derivative (47) 1, 8-
naphthyridine hydrazide exhibit cytotoxic activity against the 
HepG2 cell line (IC 50 equals 3.2 µg/ml). The results are 
comparable with 5-Fluorouracil and doxorubicin as standard 
drugs (IC 50
 
 5 and 3.56 µg/ml) respectively. 
  
Ahmed et al. [60, 61] synthesize novel Schiffs bases, thiazolidine, and 
pyrazolidine by the use of versatile synthon 4-hydroxy-2, 7-
dimethyl-1, 8-naphthyridine and evaluate for their cytotoxic activity. 
Compounds (48) (2-(2,7-Dimethyl-1, 8-naphthyridine-4-yloxy)-N-
(4-methoxybenzylidene) acetohydrazide) and (49) (N-Acetyl-2-(2,7-
dimethyl-1, 8-naphthyridine-4-yloxy)-N-(2-(4-methoxyphenyl)-4-
oxothiazolidin-3-yl) Acetamide) show the maximum cytotoxic 
activity against the HepG2 cell line with IC50 value 0.047 and 0.041 
µM, respectively. The versatile synthon 2-(2, 7-dimethyl-1, 8-
naphthyridine-4-yloxy) acetohydrazide. (50) (1, 2, 4-triazole 
incorporated 1, 8-naphthyridine) shows the maximum cytotoxic 
activity against the HepG2 cell line with the IC50
 
 value of 0.048 µM. 
Elansary et al. [62] report synthesis of various 2, 4, 5, 7-
tetrasubstituted pyrido [2, 3-d] pyrimidines and their allied 
isosteres substituted 1, 8-naphthyridines and study their anticancer 
activity. Compound, 7-(4-chlorophenyl)-5-(3-nitrophenyl)-2-phenyl-
1, 8-naphthyridine-4-amine (51) shows potent to moderate growth 
inhibitory activity. Fu et al. [63] develop a proficient synthesis of 
new functioned 1, 8-naphthyridine and chromeno [2, 3-b] quinoline 
derivatives (52) via cascade reaction of 2-chloroquinoline-3-
carbaldehyde and enaminones or cyclic 1, 3-dicarbonyl compounds. 
All the derivatives are evaluated for their cytotoxic activity in vitro 
against various cancer cells and a number of derivatives are 
established to have higher activities. 
  
Acosta et al. [45] synthesize pyrazolo [3,4-b] [1, 8] naphthyridine-5-
amines by microwave assisted organic reaction involving cyclic 
ketones and heterocyclic o-aminonitriles and the reaction is catalyzed 
by ZnCl2 leading to the new procedure. These compounds are 
evaluated for their antitumor activity against 60 different cell lines. 
Compounds, (53a) NPTR fused with cyclopentane and (53b) NPTR 
fused with cyclohexane show notable anticancer activity against tumor 
cell lines, with significant GI50
 
 values 0.62-2.18 μM/ml. 
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Graf et al. [64] investigate the reaction of cyclometallated rhodium and 
iridium complexes with 2-methyl-1,8-naphthyridine and 4-chloro-2-
methyl-1,8-naphthyridine and evaluate their cytotoxic activity 
towards the HT-29 and MCF-7 cancer cell lines. Rhodium complexes 
(54a and c), and iridium complexes (54b and d) show significant 
cytotoxic activity against both the cancer cell lines in the subordinate 
micromolar range. Amongst these complexes, maximum activity is 
calculated for (54d) with IC50 values of 1.67 μM for MCF-7 and 2.83 μM 
for HT-29. In addition, it is found that the complexes (54b) and (54d) 
attribute a somewhat more anticancer activity towards both the cell 
lines in comparison to the rhodium analogous (54a) and (54c), 
respectively. Jia et al. [65] develop a series of naphthyridinone 
derivatives analogous to Voreloxin (13) and evaluate their in vitro 
anticancer activity against HL60 cell line. Compound (E)-7-(3-
(aminomethyl)-4-(benzyloxyimino)-3-methylpyrrolidine-1-yl)-4-oxo-
1-(thiazol-2-yl)-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid (55) 
shows wide range of activity with IC50 
 
value ranging from 0.5–6.25 
mmol/l against all the tested cancer cell lines. 
 
Behalo et al. [66] synthesize a series of pyrido [2,3-d]pyrimidine and 
1,8-naphthyridine derivatives and evaluate their anticancer activity 
against MCF-7, and PC-3 cancer cell lines using MTT assay. The 
compound, 1,8-naphthridincarbonitrile (56) is found to be a most 
effective anticancer agent against PC-3 cell line with IC50 
 
Melha [68] synthesizes a series of pyrazolo pyridine substituted 1, 8-
naphthyridine derivatives and evaluate their cytotoxic activity 
against Ehrlich ascites carcinoma (EAC). Compound (58) pyrazolo 
pyridine substituted 1, 8-naphthyridine shows the best cytotoxicity 
and antioxidant activity against EAC. 
5-HT
values 
ranging from 9.47, 10.34, and 8.13 μg/ml respectively. The 
compound also shows strong anticancer activity against MCF-7 cell 
line. Tang et al. [67] synthesized a sequence of pyrrolo [2,3-b] 
pyridine compounds containing the 1,8-naphthyridine-2-one group 
and studied their anticancer activity against HT-29, H460, A549, and 
U87MG cell line and six tyrosine kinases (c-Met, VEGFR-2, EGFR, Flt-
3, PDGFR-β, and c-Kit inhibition activities. Maximum compounds 
show good to outstanding activity and pyrrolo pyridine substituted 
1,8-naphthyridine-3-carboxamide compound (57) shows Kinase 




Amongst the serotonin family, 5-HT
 receptor antagonists 
3 receptor draws much more 
interest due to the therapeutic use of 5-HT3 receptor antagonists in 
the management vomiting, nausea induced by cancer chemotherapy, 
postoperative nausea vomiting (PONV) and other clinical uses. In 
addition, several preclinical studies recommend that 5-HT3
Gautam et al. [71] studies various piperazine substituted 8-
naphthyridine-3-carboxylic acid derivatives for their 5-HT
 receptor 
antagonist may use the management of different CNS diseases [69, 70].  
3
Compound (60) (2-methoxy-1, 8-naphthyridine-3-yl) (2-methoxy 
phenylpiperazine-1-yl) methanone and (61) is selected as the lead 
compounds which show a pA2 value of 7.67. The naphthyridine-3-
carboxamide (2-Ethoxy-1, 8-naphthyridine-3-yl) [4-(3-methoxyphenyl) 
piperazin-1-yl] methanone) (62) exhibit outstanding 5-HT
 receptor 
inhibition and anxiolytic-like activity in rodent behavioral models. 
Compound (2-(4-phenylpiperazine-1-yl)-1, 8-naphthyridine 3-
carboxylic acid) (59) has good log P (3.35) and pA2 value (7.6) 
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CB1 receptor inverse agonists 
The cannabinoid-1 receptor (CB1) is present mostly in the CNS 
which is stimulated by the endocannabinoids (ECs) which are 
endogenous lipid-based retrograde neurotransmitters. A contrary 
agonist/antagonist action of the CB-1 receptor have the capacity to 
overcome food intake in both humans and other animals. Inhibition 
of CB1 receptor can be used effectively in the treatment of obesity 
[76, 77]. Duggan et al. [78] synthesize and study SAR of the CB1 
receptor adverse agonists derived from dihydro-pyrano [2, 3-b] 
pyridine and tetrahydro-1, 8-naphthyridine scaffolds. Rat food 
intake and pharmacokinetic study of compound (63) shows that 
tetrahydro-1, 8-naphthyridine bicyclic core structures, are orally 
useful in regulation of food intake and body weight in a rodent 
model. 
CB2 receptor agonists with anticancer and immunomodulatory 
activity 
Manera et al. [79] design and synthesize 1, 8-naphthyridine-4 (1H)-
on-3-carboxamide and quinoline-4 (1H)-on-3-carboxamide 
derivatives. Compound (64) (p-fluorobenzyl and carboxycycloheptyl 
amide) substituents present at 1 and 3 positions of the 1, 8-
naphthyridine-4-one nucleus, show greater affinity toward CB2 with 
a Ki of 1.0 nM. The 1-morpholino substituted compounds (65-68) 
show good CB2 affinity and CB2 versus CB1 selectivity. 
  
 
Furthermore, they find that their efficiency is restricted due to the 
presence of the substituents at C-6 of the naphthyridine ring and 4-
hydroxy-2-oxo-1, 2-dihydro-1, 8-naphthyridine derivatives 
characterize by a 4 methyl cyclohexyl amido substituted in position 
3 of the heterocyclic nucleus with higher CB2 receptor efficacy and 
preference [80]. The p-fluorobenzyl quinoline-2-one derivative (69) 
and the morpholino ethyl derivative (70) show the excellent affinity 
and selectivity and act as a full agonist and a partial agonist at the 
CB2 receptor and induce a concentration-dependent decline of cell 
capability on lymph node carcinoma of the prostate (LNCaP), cell 
line expressing the CB2 receptor [81]. Regarding CB2R affinity, the 
compounds (69 and 70) prove as compounds of interest to have a 




Saccomanni et al. [83] study the synthesis of novel aryl iodonium 
salts used as precursors for single-stage nucleophilic [18] F radio 
fluorination. The radiolabeled compound [[18] F] 1, 8-
naphthyridine-3-carboxamide (71) is effectively synthesized for in 
vivo administration, and its pre-bio-distribution is assessed with 
micro-PET/CT. The results indicate that [[18] F] CB1 is a potential 
candidate marker for distribution of CB2 receptor. Manera et al. [84] 
synthesize derivatives of quinoline and NPTR and evaluate affinity 
and selectivity for the CB2 receptor. Compounds (72 and 73) show 
the excellent affinity and selectivity profile for the CB2 receptor. 
  
 
Malfitano et al. [85] study 1, 8-naphthyridine derivatives effects and 
the defensive role of the CB receptor in various neurological 
disorders. In this case study, the immunomodulatory and anti-
inflammatory property of the designed compounds along with their 
possible intestinal absorption and blood-brain barrier (BBB) 
permeability have been found out. The test compounds, (74-76) 
show inhibition of the peripheral blood cells proliferation of the 
tested cell. The anti-proliferative effects of compound 1-benzyl, N-
cyclohexyl substituted l, 8-naphthyridine-3-carboxamide (75) and 1-
(4-fluorobenzyl), N-(4-methylcyclohexyl) substituted 1,8-
naphthyridine-3-carboxamide (76) are moderately intervened by 
the CB2 receptor. These derivatives block the cell cycle and CB91 
decline T cell activation. Compounds downregulate the expression of 
phosphorylated proteins like NF-κB, extracellular receptor kinase, 
Akt and COX-2 enzyme, CB91 inhibits the function of the CB2 
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He also studies the potential immunomodulatory activity of 1, 8-
naphthyridine and quinoline derivatives in activated lymphocytes 
isolated from multiple sclerosis patients. Compounds are found to 
block cell explosion by a mechanism that partially attributed to the 
CB2 receptor, down-regulated TNF-α production and does not 
provoke cell decrease. They also down-regulate ERK, Akt, and NF-kB 
phosphorylation. NPTR and quinoline derivatives inhibit cell 
activation markers. In multiple sclerosis patient isolated 
lymphocytes more effective than in that cell isolated from healthy 
control. In fact, 1, 8-naphthyridine-2-one derivative reduces the 
levels of the Cox-2 enzyme in lymphocytes. [86]. He also develops 
cycloheptyl substituted derivative VL15 (78) as a selective CB2 
receptor agent with high selectivity and affinity at the CB2 receptor 
and havening excellent protective role of this receptor in various 
neurological diseases with an autoimmune constituent like multiple 




Human immunodeficiency virus type 1 (HIV-1) integrase is a viral 
enzyme that catalyzes the incorporation of the viral DNA into the 
host cell DNA, an essential step for virus replication. This process is 
completed via successive strand transfer, involving elimination of 
the terminal dinucleotide from each 30-terminal of the target viral 
DNA followed by successive joining of the 30-terminal of the target 
viral DNA of the host DNA. This virus-encoded enzyme is required 
for the completion of the viral replication cycle and thus illustrates a 
very attractive target for designing antiretroviral drugs [88, 89]. 
Nagasawa et al. [90] develop an HIV-1 integrase inhibitor (79a and 
b) which shows much-improved human microsome stability up to 
75–97%. The halogenated phenyl derivatives of 1,8-naphthyridine-




Zhao et al. [91, 92] synthesize bicyclic inhibitors having a hydroxyl 
group at position 1 and 4 in 1, 8-naphthyridine-3-carboxamide 
scaffolds and evaluate their HIV1 integrase inhibitory activity. 
Amongst these amides, N-(2,4-difluorophenyl)-1-hydroxyl substituted 
1, 8-naphthyridine-3-carboxamide (80a) and N-(2,4-difluorophenyl)-
1,4-dihydroxyl substituted 1, 8-naphthyridine-3-carboxamide (80b) 
show antiviral activity in nanomolar range potencies against HIV-1 
integrase. Most of the derivatives show selectivity index more than 
20,000, and several compounds have better antiviral potencies than 
raltegravir against a group of integrase mutants consist of N155H, 
Y143R, G118R, and the double mutants G140S/Q148H and 
E138K/Q148K. He also studies substituted 1, 8-naphthyridine-3-
carboxamides integrase inhibitors (81a and b) to search the agents 
that have better potential against recombinant integrase in 
biochemical assays. Amongst the new inhibitors, compound 2-(3-(2,4-
difluorobenzylcarbamoyl)-1-hydroxy-2-oxo-1,2-dihydro-1,8-
naphthyridine-4-ylamino) ethyl acetate (81a) shows a profile against 
the panel while substituted 4-amino 1, 8-naphthyridine-3-
carboxamide (81b) exhibits the best overall absolute performance 




Massari et al. [93] describe that 1,8-naphthyridine (82), has a 
promising anti-HIV activity, which has the capability to block the 
HIV-1 Tat-mediated transcription. This lead to the discovery of 
naphthyridine derivative NM13 as the most promising compound, 
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gained from MT-4 cells. The introduction of an amino group at the 
C6 position of 1, 8-naphthyridine nucleus characterizes many of the 
potent 6-desfluoroquinolones. Benzothiazolyl derivative of 1,8-
naphthyridine-3-carboxylic acid (83) show better anti-HIV activity, 
whereas 6-amino derivative of 1,8-naphthyridine-3-carboxylic acid 
(84) bearing the pyridinyl piperazine as a C7 substituent, show 
reasonable activity along with little cytotoxic activity along with 




Non-steroidal anti-inflammatory drugs (NSAIDs) are much more 
useful drugs in the management of moderately and chronic 
inflammation, fever, and pain. However, unvarying clinical usage of 
well-known NSAIDs is associated with a wide range of unwanted 
side effects including bleeding, gastrointestinal lesions, and 
nephrotoxicity. Thus, the discoveries of the novel and 
therapeutically safe and anti-inflammatory drugs represent an 
additional challenge to the researcher [95, 96]. Due to the 
development of resistance against anti-inflammatory drugs, there is 
an increasing demand for the discovery of novel, potent and less 
toxic anti-inflammatory drugs [97, 98]. Madaan et al. [99] synthesize 
a series of 1, 8-naphthyridine-3-carboxamide derivatives (85a-c) 
and evaluate their anti-cancer and anti-inflammatory activity. The 
derivatives of 1, 8-naphthyridine-3-carboxamide substituted with 7-
chloro-N-(3-(cyclopentylamino) (85a), 7-chloro-N-(2-hydroxy-3-
oxo-1-phenyl-3-(phenylamino) (85b) and 7-chloro-6-fluoro-N-(2-
hydroxy-3-oxo-1-phenyl-3-(phenylamino) (85c) show considerable 
activities. Amongst these, compound (85c) shows effective anti-
inflammatory activity on inflammatory markers in dendritic cell 
model at 0.2 and 2 μM. It also very much declines the secretion of IL-
6, TNF-α, and IL-1-β by murine splenocytes and Tamm-Horsfall 
Protein 1 (THP-1) cells against lipopolysaccharides induced levels. 
 
 
Braccio et al. [100] synthesize 5-(alkylamino)-9-isopropyl [1, 2, 4] 
triazole derivatives of 1, 8 naphthyridines containing a CONHR 
moiety at 6 positions and evaluate their anti-inflammatory 
behavioral patterns. The compound exhibits good anti-inflammatory 
activity in rats. The most active compound (86) shows significant 
anti-inflammatory activity with percentage oedema inhibition values 
of 80% (P<0.01) and 72% (P<0.01) at the doses of 100 mg/kg 50 
mg/kg, respectively [100]. 
  
 
As new ligand of A2A
Adenosine is perhaps more important neuromodulator in the CNS and 
peripheral nervous systems, its formation generally rises under 
metabolically favorable conditions. This nucleoside controls its effects 
throughout the activation of four subtype adenosine receptors located 
on the cell surface and recognized as the A adenosine receptor  1, A2A, A2B, and A3. In the 
peripheral system, the A2AAR is located in different tissues, and then 
A2AAR agonists can be used to decrease platelet aggregation in 
thrombosis, ischemia for determining the strength of anti-
inflammatory and immunosuppressive properties. In view of all the 
above, much effort and contribution of A2AAR have been focused in the 
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last few years toward the discovery and development of selective 
A2AAR ligands [101]. Manera et al. [102] synthesize 1, 8-naphthyridine 
derivatives containing different substituent (87a-d) at position 3, 4, 
and 7 of the heterocyclic nucleus. The synthesized compounds do not 
have any affinity towards A1AR, while several of them have the 
capacity to gain an interesting activity and selectivity for the A2AAR. All 




AR, with Ki values ranges from 30.0-67.0 µM. 
  
1
Ferrarini et al. [103] synthesize derivatives of NPTR containing a 
phenyl group at position 2 and different substituents at 4 and 7 
positions. The substitution at position 7 significantly alter the 
affinity and the most attractive substitutes at this place seem to be 
by electronegative groups; as in the 7-chloro-2-phenyl-1, 8-
naphthyridine-4-ol (88) where an excellent selectivity linked with a 
good A
 adenosine receptor antagonist 
1
 
Selective AChE inhibitor 
 affinity (Ki) 0.15 µM) was found. 
 
Alzheimer’s disease (AD) is a chronic neurodegenerative, 
irreversible disorder that is clinically characterized by a successive 
loss of various cognitive and functional abilities [104]. It is the most 
general form of dementia in Western countries, which has caused 
intense economic and social impact as the aging population elevates. 
Though a lot of factors have been concerned in the AD, its etiology 
and pathogenesis remain indefinite. The ‘cholinergic hypothesis’ 
describes the most useful approaches associated with the design of 
new drugs for the management of AD. This approach is based on the 
development of drugs with an acetylcholinesterase inhibition profile 
in order to restore the deficiency of cerebral acetylcholine [105]. 
Klenc et al. [106] invent the first radiotracer targeting the GPR91, 
which is a cell surface-bound receptor that controls the cellular 
effect to hypoxia and hyperglycemia; they design and prepare a 
series of NPTR derivatives (89a and b) with excellent affinity to 
GPR91. Pharmacological assays confirm the lead compounds for 
99mTc and 18F GPR91 radiotracers within the series. 
  
 
Other activities  
Potent gastric antisecretory properties 
Gastric endoscopic submucosal dissection (ESD) can cause artificial 
gastric ulcers, and there is no compromise regarding the possible 
perioperative management in conditions of anticipation of intra-or 
postoperative bleeding and support of healing. The gastric 
antisecretory effects of various naphthyridine derivatives have 
attempted to enter as a therapeutic drug for the healing of peptic 
ulcer [107-109]. Santilli et al. [110] and they describe the syntheses 
of 2-oxo-l, 8-naphthyridine-3-carboxylic acid derivatives (90a and b) 
containing efficient gastric antisecretory activity. The ethyl ester 4-
amino-l-ethyl-l,2-dihydro-2-oxo 1,8-naphthyridine-3-carboxylic acid 
(90a) and ester of substituted 4-(4-methyl-l-piperazinyl) l, 8-
naphthyridine-3 carboxylic acid (90b) show good gastric 
antisecretory property and are chosen for further exhaustive 
assessment. 
Atypical antipsychotic agents 
Sekhar et al. [111] provide a series of 2,5-disubstituted thiazolyl-
phenylethyl-piperazine derivatives of 1, 8-naphthyridine scaffold in 
search of a novel, atypical antipsychotic drugs. Compound 2-(4-(4-
(2-amino-5-methylthiazol-4-yl) phenethyl) piperazine-1-yl)-1, 8-
naphthyridine-3-carbonitrile (91) exhibits good antipsychotic 
activity amongst the synthesized derivatives with 5-HT 2A/D2 ratio 
of 1.1286.
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Ferrarini et al. [112, 113] synthesize 1, 8-naphthyridine derivatives, 
containing 2-cycloalkylamino-3-phenyl as substituents at position 6-
and 7 (92 and93) and 2, 7-di (N-cycloamino)-3-phenyl substituted 
compound (94) and assess their antiplatelet activity. All the 
synthesized derivatives demonstrate a significant antiplatelet action in 
the test with arachidonate and collagen comparable to that of standard 
drug indomethacin. In the test with ADP, compound (94) exhibits a 
considerable activity. The presence of morpholinyl or a piperidinyl like 
a moiety at position 2 and a halogen group like chlorine or a methoxy 
group at position 7 of the NPTR nuclei appear to favor a good activity. 
  
 
DNA stabilizing agents 
Naik et al. [114] describe the synthesis and molecular docking 
studies of new benzo [b] [1, 8] naphthyridines. The docking results 
reveal that the synthesized compounds favor the binding with AT-
rich region of ds-DNA. The highest binding energy was found for 
benzo [b] [1, 8] naphthyridine-5-thiol (95) and it is-7.16 
(kcal/mol). It offers a promising agent as an enantioselective 
binder with ds-DNA than the other compounds of benzo [b] [1, 8] 
naphthyridines. Photo irradiated at 365 nm, to benzo [1, 8]-
naphthyridines find to support the photocleavage of plasmid 
pUC19 DNA. Dhamodharan et al. [115] observe the synthesis of 
bispyridinium and bisquinolinium derivatives of NPTR and report 
their relations between the human telomeric DNA and promoter 
G-quadruplex building DNAs. The bisquinolinium ligands bind 
strongly and selectively to quadruplex DNAs at low ligand 
concentration. The fluorescent intercalator displacement (FID) 
assay is estimating that naphthyridine bisquinolinium ligands (96a 
and b) create good binding affinity and also have selectivity for 
quadruplex DNAs over duplex DNA. 
  
 
Acyl-CoA: cholesterol acyltransferase inhibitor 
Ban et al. [116] synthesize 4-Aryl-1, 8-naphthyridine-2 (1H)-on-
3-yl urea derivatives with hydrophilic groups for the purpose of 
getting better aqueous solubility and pharmacokinetics 
property. Compound SMP-797, 1-(4-amino-2, 6-diisopropyl-
phenyl)-3-(1-butyl-4-(3-(3-hydroxypropoxy) phenyl)-2-oxo-1, 2-
dihydro-1, 8-naphthyridine-3-yl) urea (97) having (4-
aminophenyl) ureido and 3-(hydroxypropoxyphenyl) moieties 
shows effective Acyl-CoA: cholesterol acyltransferase (ACAT) 
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MEK (mitogen-activated protein kinase) inhibitors 
Kanouni et al.[117] synthesize and develop 1, 8-naphthyridine-2,5-
dione (98a-d) and evaluate MEK kinase inhibitory activity. Most of 
the compounds show activity against MEK1 kinase. All analogs show 
activity in sub-micromolar range against MEK through assays in 
cellular and enzymatic levels. 
  
 
Phosphodiesterase (PDE 4) inhibitors 
Takayama et al. [118] prepare new and phosphodiesterase (PDE4) 
inhibitor. The compounds show selective inhibitory activities 
against PDE4 obtained from human peripheral blood cells and are 
inactively applicable to other PDE types (1, 2, 3, 5). The compound 4, 
5, 7-Trimethyl-1-phenyl-1, 8-naphthyridine-2 (1H)-one (99)-YM-
10335) having 1, 8-naphthyridine-2 (1H)-one skeleton completely 
differ structurally from rolipram and is selected as a lead compound. 
The derivatives also produce good inhibitory activities against TNF-
α release (in vitro) and carrageenan-induced pleurisy (in vivo) assay.  
Inhibitors of αvβ
The progress of effective and safe medication for the management of 
osteoporosis there still remains a growing field of developing 
research. Osteoporosis occurs due to the difference between the 
natural processes of bone resorption and bone growth. The first step 
in bone resorption is the unique function of the osteoclast cells 
which is regulated by glycoprotein, α
3 
Vβ3 integrin. An unusual way to 
interrupt this mechanism is the minimization of osteoclast cells 
activity by introducing αVβ3 integrin inhibitors [119]. Hartner et al. 
[120] synthesize 3(S)-(6-Methoxypyridin-3-yl)-3-{2-oxo-3-[3-(5, 6, 
7, 8-tetrahydro-[1, 8]-naphthyridine-2-yl) propyl]-imidazolidin-1-
yl} propionic acid (100) and identify it as an effective and selective 
αvβ3 receptor antagonist. It has an outstanding in vitro profile with 
an IC50 value of 0.08 µM which is an important unbound part in 
human plasma and serves as a remarkable pharmacokinetics profile 
for the dog, rats, and rhesus monkey. Nagarajan et al. [121] describe 
the synthesis and αvβ3 inhibitory activity of numerous small 
molecules like 2-(2-(4-(2-(5, 6, 7, 8-tetrahydro-1, 8-naphthyridine-
2-yl) ethoxy) phenyl) cyclopropyl) acetic acid (101). Most of the 
compounds show remarkable selectivity over αvβ6
 
Anticonvulsant and CNS activity 
. 
Despite the wide and increasing range of antiepileptic drugs 
available for treatment, around 30% of epileptic patients experience 
faulty seizure control. Again, further 25% of patients fell serious 
adverse effects. Thus, there is a need to develop more efficient 
antiepileptic drugs that would be endowed with an improved safety 
profile. Recently, a lot of fused pyrimidine compounds are developed 
as effective drug molecules. Such an important family of the 
compounds is quinazolinones which are the constituents of about 
150 naturally existing alkaloids and drugs. Some NPTR derivatives 
also show remarkably good anticonvulsant and CNS depressant 
activity [122]. Stuk et al. [123] study the NPTR derivatives having 
different moieties (102) for anxiolytic activity which may be due to 
the partial agonist action of benzodiazepine at the site of the GABAA
 
 
receptor. Lorrio et al. [124] investigate the neuroprotective profile 
of ethyl 5-amino-2-methyl-6, 7, 8, 9-tetrahydro benzo [b] [1, 8] 
naphthyridine-3-carboxylic acid ester (103-ITH12246) through in 
vitro models for Alzheimer’s disease. They also find the 
pharmacological activities of ITH12246 and evaluate its capacity to 
counter the memory mutilation elicited by scopolamine, a 
muscarinic antagonist characterized to approve memory loss. They 
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Wang et al. [125] synthesize the derivatives containing an imidazo 
[1,2-α] [1, 8] naphthyridine core and a side chain connected with 
amide bond (104a-RO8191 and b) and evaluate the HCV entry 
inhibitory activity in hepatitis C virus cell culture system. Among 
these compounds, a few compounds exhibit outstanding anti-HCV 
activity with EC50 value ranges from 0.017-0.159 µM and low 
toxicity (CC50
The finding of simple organic compounds endowed with good 
antimicrobial and antioxidant properties is of growing concern in 
the food industries. Preservation and protection of industrial food 
containing polyunsaturated fatty acids (eicosapentaenoic (20:5 ω-3) 
acid) have become a hot subject and growing interest because of 
their importance in human nutrition. For example, Omega-3-
Polyunsaturated fatty acids provide a number of health benefits 
related to cardiovascular disease, immune disorders, inflammation 
condition, allergic manifestations and the occurrence of diabetes. 
Several compounds having antioxidant activity have been used to 
slow down the radicals associated with oxidative reactions. 
However, some of them are known to produce toxic and 
carcinogenic side effects in animal models [126,127]. The discovery 
of compounds that can demonstrate both antimicrobial and 
antioxidant activities having no or zero side effects are most 
welcome. Nam et al. [128] demonstrate that the C7 unsubstituted 
tetrahydro-1, 8-naphthyridine-3-ol (105a-d) have greater trapping 
activity than α tocopherol in inhibiting autoxidations in benzene. 
The C7-mono and dialkyl analogs exhibit higher antioxidant activity 
in benzene, as found out by a recently developed peroxyl radical 
clock. The closest α-TOH analogs (naphthyridineol-based 
tocopherol, N-TOH) show outstanding inhibition of the oxidation of 
cholesteryl esters in human LDL and secure endogenous α-TOH. 
 
>25 µM). These novel anti-HCV compounds exhibit 
antiviral activity by a different mechanism of action as that of 
RO8191 by targeting the viral entrance route.  
Antioxidants activity 
 
Yu et al. [129] study the effect of a peripheral disulfide bridge 
substituent on the phenolic hydroxyl bond dissociation energy (BDE) 
and the ionization potential (IP) of 1,8-naphthyridine diol for 
antioxidant properties of derivatives (106 a-b and107 a-d). Comparing 
with naphthalene diol, the substituent of a peripheral disulfide bridge 
group is very proficient in dropping the BDE, while the additions of 
nitrogen atoms into the naphthalenic ring only slight changes the BDE 
of O-H bond but considerably increase the IP. It is comparable also on 
consideration of the stereoelectronic behavior of the heterocyclic ring 





Aljamal and Badawneh [130] investigate the antilipolytic activity of 
the new NPTR derivatives (108a and b) on lipolysis induced rat fat 
cell β-adrenoceptors by isoprenaline and alprenolol. The NPTR 
derivatives substituted with 7-hydroxy-2-(4'-methoxybenzylamine)-
6-nitro-3-phenyl (108a) and 7-methoxy-N2-(4-methoxybenzyl)-3-





Pal et al. 
Int J Pharm Pharm Sci, Vol 11, Issue 1, 17-37 
 
33 
Review articles related to 1, 8-naphthyridine  
Recently, there are significant numbers of reviews which have been 
published related to the chemistry, synthesis and biological activity 
of 1, 8-naphthyridine and bioactivities of the 1, 8-naphthyridine 
metal complexes and multiple activities of 1, 8-naphthyridine [131].  
CONCLUSION  
The 1,8-naphthyridine ring is an important pharmacophore in modern 
drug discovery. Attention has been gradually more given to the 
synthesis of 1,8-naphthyridine derivatives as a source of new 
biological agents. The 1,8-naphthyridine derivatives are a resource for 
further medicinal research. The information gained by various 
researches has recommended that substituted 1,8-naphthyridines and 
heterocycles, which are the structural isosteres of nucleotides, allocate 
them to interact simply with the biopolymers, have pharmacological 
activity with lower toxicities. Changes in the 1,8-naphthyridine 
structures have offered high biological activities that have established 
a start point for the development of novel therapeutic drugs with 
improved potency and low toxicity. The present review highlights the 
various synthesized 1,8-naphthyridines (NPTR) and their derivatives 
showing multiple activities such as analgesic, anti-inflammatory, 
anticancer, antioxidant, antitubercular, antiviral, antilipolytic 
antiplatelets, Anticonvulsant and CNS, antiplatelet, acetyl 
cholinesterase inhibitory, and diuretic activity. 
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